BEZ235 (NVP-BEZ235)PI3K/mTOR inhibitor,ATP-competitve CAS# 915019-65-7 |
- BEZ235 Tosylate
Catalog No.:BCC1416
CAS No.:1028385-32-1
- GSK2126458
Catalog No.:BCC3884
CAS No.:1086062-66-9
- VS-5584 (SB2343)
Catalog No.:BCC2047
CAS No.:1246560-33-7
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- PIK-294
Catalog No.:BCC4995
CAS No.:900185-02-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 915019-65-7 | SDF | Download SDF |
PubChem ID | 11977753 | Appearance | Powder |
Formula | C30H23N5O | M.Wt | 469.55 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Dactolisib; NVP-BEZ235 | ||
Solubility | DMSO : 5.2 mg/mL (11.07 mM; Need ultrasonic and warming) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile | ||
SMILES | CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 | ||
Standard InChIKey | JOGKUKXHTYWRGZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | BEZ235 (NVP-BEZ235) is a dual ATP-competitive inhibitor of PI3K and mTOR for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively. | ||||||
Targets | p110α | p110γ | p110δ | p110β | ATR | ||
IC50 | 4 nM | 5 nM | 7 nM | 75 nM | 21 nM |
Cell experiment: [1] | |
Cell lines | MOLT-4 and CEM-R cells |
Preparation method | The solubility of this compound in DMSO is <10 mm. general tips for obtaining a higher concentration: please warm the tube at 37 °c 10 minutes and> |
Reacting condition | 500 nM, for cell cycle inhibition 200 nM, 16 hours for pRb decrease |
Applications | Flow cytometric analysis of PI-stained T-ALL cells treated with BEZ235 for 16 hours documented an increase in G0/G1 phase cells and a concomitant decrease in S and G2-M phases in both MOLT-4 and CEM-R cell lines. A decrease in the amount of Ser807/811 pRb was detected in MOLT-4 and CEM-R cells treated with 200 nmol/L NVP-BEZ235 for 16 hours, whereas total pRb levels remained unchanged. |
Animal experiment: [2] | |
Animal models | Female athymic nude-Foxn1nu mice injected with BT474-VH2 cells |
Dosage form | Oral administration, 40 mg/kg, once daily for 21 days |
Application | The antitumor activity of BEZ235 was studied in a xenograft model derived from HER2-amplified BT474 breast cancer cells engineered to express either the H1047R hotspot mutation or the empty vector (pBABE). BEZ235 treatment resulted in suppressed tumor growth. The H1047R-overexpressing tumors responded better to the BEZ235 treatment when compared with mock controls. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer research, 2010, 70(20): 8097-8107. [2] Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer research, 2008, 68(19): 8022-8030. |
BEZ235 (NVP-BEZ235) Dilution Calculator
BEZ235 (NVP-BEZ235) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1297 mL | 10.6485 mL | 21.297 mL | 42.594 mL | 53.2425 mL |
5 mM | 0.4259 mL | 2.1297 mL | 4.2594 mL | 8.5188 mL | 10.6485 mL |
10 mM | 0.213 mL | 1.0648 mL | 2.1297 mL | 4.2594 mL | 5.3242 mL |
50 mM | 0.0426 mL | 0.213 mL | 0.4259 mL | 0.8519 mL | 1.0648 mL |
100 mM | 0.0213 mL | 0.1065 mL | 0.213 mL | 0.4259 mL | 0.5324 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BEZ235 is an imidazoquinoline derivative inhibiting both PI3K and mTOR kinases with low nanomolar IC50s. It was well tolerated in preclinical animal studies as well as in clinical trials with manageable gastrointestinal side-effects[1, 2]. It competes with ATP by binding to the ATP-binding site of kinases and reversibly reduces enzyme activity, resulting in growth arrest of tumor cells in G1 phase[1]. Besides the inhibition of cell growth, BEZ235 blocks VEGF-induced angiogenesis[3]. It may also inhibit DNA-PKcs[4].
BEZ235 has shown potential anti-tumor activity both in vitro and in vivo. It inhibited growth of multiple cancer cell lines independently of mutation status in PI3K pathway[5]. In xenograft mice models, it blocked PI3K signaling and showed antitumor activity[1, 5]. Combination study demonstrated that it enhances the efficacy of temozolomide[1].
Clinical data shows anti-tumor activity of BEZ235 treatment, especially in cancer patients with deregulated PI3K signaling pathway. This compound is currently under investigation in multiple clinical trials either as monotherapy or in combination with other agents.
References:
1. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
2. Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399-2408.
3. Schnell CR, Stauffer F, Allegrini PR et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-6607.
4. Mukherjee B, Tomimatsu N, Amancherla K et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 2012; 14: 34-43.
5. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
- Palomid 529
Catalog No.:BCC3905
CAS No.:914913-88-5
- INCB024360 analogue
Catalog No.:BCC1647
CAS No.:914471-09-3
- R788 disodium hexahydrate
Catalog No.:BCC5127
CAS No.:914295-16-2
- 9-Aminocamptothecin
Catalog No.:BCN2453
CAS No.:91421-43-1
- 9-Nitrocamptothecin
Catalog No.:BCN8448
CAS No.:91421-42-0
- 25-O-ethylcimigenol-3-O-beta-D-xylopyranoside
Catalog No.:BCN1309
CAS No.:914086-57-0
- PluriSIn #1 (NSC 14613)
Catalog No.:BCC2305
CAS No.:91396-88-2
- Lu AA 47070
Catalog No.:BCC7977
CAS No.:913842-25-8
- CS 2100
Catalog No.:BCC6221
CAS No.:913827-99-3
- SC75741
Catalog No.:BCC5448
CAS No.:913822-46-5
- Ropinirole HCl
Catalog No.:BCC4939
CAS No.:91374-20-8
- 1''-Hydroxyerythrinin C
Catalog No.:BCN4066
CAS No.:913690-46-7
- MDV3100 (Enzalutamide)
Catalog No.:BCC1268
CAS No.:915087-33-1
- 3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan
Catalog No.:BCC8601
CAS No.:915095-94-2
- Bakkenolide IIIa
Catalog No.:BCN7352
CAS No.:915289-60-0
- Cot inhibitor-2
Catalog No.:BCC1497
CAS No.:915363-56-3
- Cot inhibitor-1
Catalog No.:BCC1496
CAS No.:915365-57-0
- ABC294640
Catalog No.:BCC4192
CAS No.:915385-81-8
- WAY 316606
Catalog No.:BCC2052
CAS No.:915759-45-4
- Dovitinib (TKI258) Lactate
Catalog No.:BCC6473
CAS No.:915769-50-5
- Momordicine I
Catalog No.:BCN3058
CAS No.:91590-76-0
- Benidipine HCl
Catalog No.:BCC4395
CAS No.:91599-74-5
- TCS 1102
Catalog No.:BCC4063
CAS No.:916141-36-1
- AC 55541
Catalog No.:BCC3951
CAS No.:916170-19-9
Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy.[Pubmed:27278249]
Int J Oncol. 2016 Aug;49(2):657-65.
The aberrant activation of PI3K/Akt/mTOR signaling pathway plays an important role in the oncogenesis, prognosis and chemotherapy resistance of neuroblastoma. However, NVP-BEZ235, a potent dual PI3K and mTOR inhibitor have not shown beneficial effects on neuroblastoma especially in terms of apoptosis induction as a single agent. We therefore attempted to explore an effective combination regimen to enhance the anticancer activity of NVP-BEZ235. Interestingly, we found that oridonin, a natural biologically active compound extracted from the Chinese medicinal herb Rabdosia rubescens, combined with NVP-BEZ235 markedly induced apoptosis of neuroblastoma cells. Notably, the synergistic activation of the apoptotic pathway was accompanied with enhanced autophagy as evidenced by significant decreased p62 expression as well as upregulated conversion of LC3-II. Suppression of the Beclin-1, a core component of the autophagy machinery, by means of shRNA resulted in diminished synergistic antitumor effect. Furthermore, the co-treatment with oridonin and NVP-BEZ235 was also much more effective than either agent alone in inhibiting the growth of neuroblastoma xenografts and in inducing tumor cells apoptosis. Taken together, our results suggest that the combination of NVP-BEZ235 and oridonin is a novel and potential strategy for neuroblastoma therapy.
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.[Pubmed:27542970]
BMC Cancer. 2016 Aug 19;16:657.
BACKGROUND: Glioblastomas (GBMs) are highly malignant brain tumours with a poor prognosis, and current cytotoxic regimens provide only a limited survival benefit. The PI3K/Akt/mTOR pathway has been an attractive target for therapy due to its high activation in GBMs as well as other cancers. The dual pan-PI3K/mTOR kinase inhibitor dactolisib (NVP-BEZ235) is an anti-neoplastic compound currently under investigation. However, little is known about its efficacy in human GBMs. We aimed at evaluating the efficacy of dactolisib in human glioblastoma cells, as well as in murine models carrying human GBM xenografts. METHODS: To assess the effect of dactolisib in vitro, MTS assay, manual cell count, BrdU incorporation and Annexin V staining experiments were used to observe growth and apoptosis. Furthermore, Akt phosphorylation (S473), a downstream target of PI3K, was explored by western blotting. Animal studies utilizing orthotopic xenograft models of glioblastoma were performed in nude rats and NOD/SCID mice to monitor survival benefit or inhibition of tumor growth. RESULTS: We found that dactolisib in vitro shows excellent dose dependent anti-growth properties and increase in apoptosis. Moreover, dose dependent inhibition of Akt phosphorylation (S473), a downstream effect of PI3K, was observed by western blotting. However, in two independent animal studies utilizing nude rats and NOD/SCID mice in orthotopic xenograft models of glioblastoma, we observed no survival benefit or inhibition of tumour growth. Severe side effects were observed, such as elevated levels of blood glucose and the liver enzyme alanine transaminase (ALT), in addition to diarrhoea, hair loss (alopecia), skin rash and accumulation of saliva in the oral cavity. CONCLUSION: Taken together, our results suggest that despite the anti-neoplastic efficacy of dactolisib in glioma treatment in vitro, its utility in vivo is questionable due to toxicity.
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.[Pubmed:27347108]
Oncol Lett. 2016 Jul;12(1):102-106.
Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway performs a central role in tumorigenesis and is constitutively activated in many malignancies. As a novel dual PI3K/mTOR inhibitor currently undergoing evaluation in a phase I/II clinical trial, NVP-BEZ235 indicates a significant antitumor efficacy in diverse solid tumors, including colorectal cancer (CRC). Autophagy is a catabolic process that maintains cellular homeostasis and reduces diverse stresses through lysosomal recycling of the unnecessary and damaged cell components. This process is also observed to antagonize the antitumor efficacy of PI3K/mTOR inhibitor agents such as NVP-BEZ235, via apoptosis inhibition. In the present study, we investigated anti-proliferative and apoptosis-inducing ability of NVP-BEZ235 in SW480 cells and the crosstalk between autophagy and apoptosis in SW480 cells treated with NVP-BEZ235 in combination with an autophagy inhibitor. The results revealed that, NVP-BEZ235 effectively inhibit the growth of SW480 cells by targeting the PI3K/mTOR signaling pathway and induced apoptosis. The inhibition of autophagy with 3-methyladenine or chloroquine inhibitors in combination with NVP-BEZ235 in SW480 cells enhanced the apoptotic rate as componets to NVP-BEZ235 alone. In conclusion, the findings provide a rationale for chemotherapy targeting the PI3K/mTOR signaling pathway presenting a potential therapeutic strategy to enhance the efficacy of dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with an autophagy inhibitor in CRC treatment and treatment of other tumors.
Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.[Pubmed:27894954]
Cancer Lett. 2017 Mar 1;388:12-20.
NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor that shows dramatic effects on many tumors, but its effects on cervical carcinoma cells are largely unknown. In the present study, we investigated the effects of NVP-BEZ235 on the proliferation and invasion of cervical carcinoma cells in vitro and clarified its mechanism of action. In cellular settings with human cervical carcinoma cell lines, this molecule effectively and specifically blocked dysfunctional PI3K/mTOR pathway activation, suppressed cell growth in a time- and concentration-dependent manner, led to G1 cell cycle arrest, and induced apoptosis. NVP-BEZ235 suppressed HeLa cell invasiveness and metastasis by inhibiting the PI3K/Akt/MMP-2 pathway. We further demonstrated that NVP-BEZ235 treatment in combination with cisplatin or carboplatin induced a synergistic anti-tumoral response in cervical carcinoma cells. These findings suggested that NVP-BEZ235 could regulate growth and invasion of cervical carcinoma cells; thus it may provide a potential therapy for cervical carcinoma.